

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## INTERVENTIONAL PROCEDURES PROGRAMME

### Equality impact assessment

#### IPG732 Bioresorbable stent implantation for treating coronary artery disease

The impact on equality has been assessed during guidance development according to the principles of the NICE Equality scheme.

#### Scoping

1. Have any potential equality issues been identified during the scoping process (development of the scope or discussion at the Committee meeting), and, if so, what are they?

Age: Prevalence rates of CAD are higher in men and older people (aged over 65 years).

Socioeconomic background: Death rates from coronary artery disease are higher in the lower socioeconomic groups.

Race: Underlying risk factors are more common in specific ethnic groups e.g. type 2 diabetes (Asians) and hypertension (Afro-Caribbean)

Disability: Some people with advanced CAD may be covered under disability legislation in the Equality Act 2010 if symptoms substantially affect the ability to carry out day to day activities for longer than 12 months. Many may have a co-existing long term-condition.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? (If there are exclusions listed in the scope (for example, populations, treatments or settings), are these justified?)

It was considered that these issues would not have an impact on the assessment of the procedure.

3. Has any change to the scope (such as additional issues raised during the Committee meeting) been agreed to highlight potential equality issues?

No

4. Have any additional stakeholders related to potential equality issues been identified during the committee meeting, and, if so, have changes to the stakeholder list been made?

No

**Kevin Harris**

**Approved by Programme Director and Clinical Advisor for IP**

**Date:** 15/06/2022

### **Consultation**

1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how?

Not applicable

2. Have any other potential equality issues been raised in the overview, specialist adviser questionnaires or patient commentary, and, if so, how has the Committee addressed these?

No

3. Have any other potential equality issues been identified by the Committee, and, if so, how has the Committee addressed these?

No

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access a technology or intervention

compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

Not applicable

6. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligation to promote equality?

Not applicable

7. Have the Committee's considerations of equality issues been described in the consultation document, and, if so, where?

No

**Kevin Harris**

**Approved by Programme Director and Clinical Advisor for IP**

**Date:** 15/06/2022

## Final interventional procedures document

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these?

No

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access a technology or intervention compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

Not applicable

3. If the recommendations have changed after consultation, is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

Not applicable

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

Not applicable

5. Have the Committee's considerations of equality issues been described in the final interventional procedures document, and, if so, where?

Not applicable

**Anastasia Chalkidou**

**Approved by Associate Director**

**Date: 15/6/2022**